Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5002 Target Snapshot

Nuclear receptor subfamily 4 group A member 2 · SINGLE PROTEIN · Homo sapiens

333Compounds
254Assays
8Approved Drugs
323.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P43354. Use UniProt P43354 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P43354 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Nuclear receptor subfamily 4 group A member 2 as ChEMBL target CHEMBL5002, mapped to UniProt P43354. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Nuclear receptor subfamily 4 group A member 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5002
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P43354
Nuclear receptor subfamily 4 group A member 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Nuclear receptor subfamily 4 group A member 2 is the right protein anchor across sources, using UniProt P43354 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNuclear receptor subfamily 4 group A member 2
UniProt AccessionP43354
Component TypeProtein
Sequence Length598 aa

Nuclear receptor subfamily 4 group A member 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Nuclear receptor subfamily 4 group A member 2, mapped to UniProt P43354. Sequence length is 598 aa.

Mapped IDP43354
Review nameNuclear receptor subfamily 4 group A member 2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

8
Approved
2
Phase III
3
Phase II
Assay Mix

Activity Type Distribution

IC50121.0
EC50171.0
KD31.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL399603 9.1 EC50 0.8 Preclinical
CHEMBL399807 8.46 EC50 3.5 Preclinical
CHEMBL401032 8.41 EC50 3.9 Preclinical
CHEMBL399602 8.39 EC50 4.1 Preclinical
CHEMBL5405485 8.0 EC50 10.0 Preclinical
CHEMBL4473232 7.85 EC50 14.0 Preclinical
CHEMBL5427562 7.68 EC50 21.0 Preclinical
CHEMBL5086921 7.62 EC50 24.0 Preclinical
CHEMBL4579076 7.6 EC50 25.0 Preclinical
CHEMBL247879 7.58 EC50 26.0 Preclinical
Distribution

pChEMBL Value Distribution

34
5.0
28
5.5
21
6.0
21
6.5
14
7.0
9
7.5
4
8.0
0
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

PITAVASTATIN
CHEMBL1201753
Approved 2009
Assay Landscape

Assay Landscape

254
Total Assays
198
Tested Compounds
2
Assay Types
Binding — 253 assays, 198 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 215 162 5.4
single protein format 31 29 5.1
assay format 7 7 6.2
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine